Cargando…
Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice
Exposure to high concentrations of hydrochloric acid (HCl) can lead to severe acute and chronic lung injury. In the aftermath of accidental spills, victims may be treated for the acute symptoms, but the chronic injury is often overlooked. We have developed a mouse model of acute and chronic lung inj...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676235/ https://www.ncbi.nlm.nih.gov/pubmed/36419627 http://dx.doi.org/10.3389/fphar.2022.1034464 |
_version_ | 1784833547302862848 |
---|---|
author | Solopov, Pavel A. Colunga Biancatelli, Ruben Manuel Luciano Dimitropolou, Christiana Day, Tierney Catravas, John D. |
author_facet | Solopov, Pavel A. Colunga Biancatelli, Ruben Manuel Luciano Dimitropolou, Christiana Day, Tierney Catravas, John D. |
author_sort | Solopov, Pavel A. |
collection | PubMed |
description | Exposure to high concentrations of hydrochloric acid (HCl) can lead to severe acute and chronic lung injury. In the aftermath of accidental spills, victims may be treated for the acute symptoms, but the chronic injury is often overlooked. We have developed a mouse model of acute and chronic lung injury, in which the peak of acute lung injury occurs on the day 4 after HCl exposure. We have also demonstrated that HSP90 inhibitors are effective antidotes when administered starting 24 h after HCl. In this study we examined the hypothesis that the novel oral HSP90 inhibitor TAS-116 can effectively ameliorate HCl-induced lung injury even when treatment starts at the peak of the acute injury, as late as 96 h after HCl. C57BI/6J mice were intratracheally instilled with 0.1N HCl. After 24 or 96 h, TAS-116 treatment began (3.5, 7 or 14 mg/kg, 5 times per week, p. o.) for either 2,3 or 4 or weeks. TAS-116 moderated the HCl-induced alveolar inflammation, as reflected in the reduction of white blood cells and total protein content in bronchoalveolar lavage fluid (BALF), overexpression of NLRP3 inflammasome, and inhibited the activation of pro-fibrotic pathways. Furthermore, TAS-116 normalized lung mechanics and decreased the deposition of extracellular matrix proteins in the lungs of mice exposed to HCl. Delayed and shortened treatment with TAS-116, successfully blocked the adverse chronic effects associated with acute exposure to HCl. |
format | Online Article Text |
id | pubmed-9676235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96762352022-11-22 Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice Solopov, Pavel A. Colunga Biancatelli, Ruben Manuel Luciano Dimitropolou, Christiana Day, Tierney Catravas, John D. Front Pharmacol Pharmacology Exposure to high concentrations of hydrochloric acid (HCl) can lead to severe acute and chronic lung injury. In the aftermath of accidental spills, victims may be treated for the acute symptoms, but the chronic injury is often overlooked. We have developed a mouse model of acute and chronic lung injury, in which the peak of acute lung injury occurs on the day 4 after HCl exposure. We have also demonstrated that HSP90 inhibitors are effective antidotes when administered starting 24 h after HCl. In this study we examined the hypothesis that the novel oral HSP90 inhibitor TAS-116 can effectively ameliorate HCl-induced lung injury even when treatment starts at the peak of the acute injury, as late as 96 h after HCl. C57BI/6J mice were intratracheally instilled with 0.1N HCl. After 24 or 96 h, TAS-116 treatment began (3.5, 7 or 14 mg/kg, 5 times per week, p. o.) for either 2,3 or 4 or weeks. TAS-116 moderated the HCl-induced alveolar inflammation, as reflected in the reduction of white blood cells and total protein content in bronchoalveolar lavage fluid (BALF), overexpression of NLRP3 inflammasome, and inhibited the activation of pro-fibrotic pathways. Furthermore, TAS-116 normalized lung mechanics and decreased the deposition of extracellular matrix proteins in the lungs of mice exposed to HCl. Delayed and shortened treatment with TAS-116, successfully blocked the adverse chronic effects associated with acute exposure to HCl. Frontiers Media S.A. 2022-11-07 /pmc/articles/PMC9676235/ /pubmed/36419627 http://dx.doi.org/10.3389/fphar.2022.1034464 Text en Copyright © 2022 Solopov, Colunga Biancatelli, Dimitropolou, Day and Catravas. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Solopov, Pavel A. Colunga Biancatelli, Ruben Manuel Luciano Dimitropolou, Christiana Day, Tierney Catravas, John D. Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice |
title | Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice |
title_full | Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice |
title_fullStr | Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice |
title_full_unstemmed | Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice |
title_short | Optimizing antidotal treatment with the oral HSP90 inhibitor TAS-116 against hydrochloric acid-induced pulmonary fibrosis in mice |
title_sort | optimizing antidotal treatment with the oral hsp90 inhibitor tas-116 against hydrochloric acid-induced pulmonary fibrosis in mice |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676235/ https://www.ncbi.nlm.nih.gov/pubmed/36419627 http://dx.doi.org/10.3389/fphar.2022.1034464 |
work_keys_str_mv | AT solopovpavela optimizingantidotaltreatmentwiththeoralhsp90inhibitortas116againsthydrochloricacidinducedpulmonaryfibrosisinmice AT colungabiancatellirubenmanuelluciano optimizingantidotaltreatmentwiththeoralhsp90inhibitortas116againsthydrochloricacidinducedpulmonaryfibrosisinmice AT dimitropolouchristiana optimizingantidotaltreatmentwiththeoralhsp90inhibitortas116againsthydrochloricacidinducedpulmonaryfibrosisinmice AT daytierney optimizingantidotaltreatmentwiththeoralhsp90inhibitortas116againsthydrochloricacidinducedpulmonaryfibrosisinmice AT catravasjohnd optimizingantidotaltreatmentwiththeoralhsp90inhibitortas116againsthydrochloricacidinducedpulmonaryfibrosisinmice |